FT538 in Subjects With Advanced Hematologic Malignancies
A Phase I, Open-Label, Multicenter Study of FT538 as Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination With Monoclonal Antibodies in Relapsed/Refractory Multiple Myeloma
Sponsor: Fate Therapeutics
Terminated
This study was terminated by the Sponsor.
Other terminated trials from Fate Therapeutics
Other AML, Adult trials with similar outcome
This PHASE1 trial investigates AML, Adult and Acute Myeloid Leukemia and is currently terminated or withdrawn. Fate Therapeutics leads this study, which shows 10 recorded versions since 2020 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Oct 2023 — Jul 2024 [monthly]
Terminated PHASE1
Status: Active Not Recruiting → Terminated
-
Jun 2023 — Oct 2023 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
▶ Show 5 earlier versions
-
Jun 2022 — Jun 2023 [monthly]
Recruiting PHASE1
-
Nov 2021 — Jun 2022 [monthly]
Recruiting PHASE1
-
Apr 2021 — Nov 2021 [monthly]
Recruiting PHASE1
-
Jan 2021 — Apr 2021 [monthly]
Recruiting PHASE1
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE1
First recorded
Oct 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Fate Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .